Driving Global Policy and Inspiring Change for Patients
Pfizer partners with the metastatic breast cancer (mBC) community to support initiatives and organizations that help people with mBC. As part of the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC mBC Challenge) initiative, launched in 2015, we have partnered with the Union for International Cancer Control (UICC) to award more than $1.3 million in funding to organizations to support projects that address the specific needs of mBC patients globally. Â
At this yearâs World Cancer Congress, Pfizer will present the latest in policy research through interactive workshops, presentations and activities to encourage the mBC global community to center their focus on patients. Pfizer will have two symposiums, âInitiatives to Support the Patient Journeyâ and âPatient Driven Data to Drive Changeâ which will focus on mBC policy gaps, patient data and improving the patient journey. We will also support the SPARC Metastatic Breast Cancer Challenge Master Course Workshop, âAddressing gaps in information, patient support and policy for mBC patients."
Addressing Metastatic Breast Cancer Unmet Needs Through Patient-Focused Policies
Living with metastatic breast cancer remains an ongoing battle for both patients and their caregivers, and resources outside of medicine are vital for improving quality of life. This year at WCC, PfizerÂ will present the latest in policy research through interactive workshops, presentations and activities to encourage the mBC global community to center their focus on patients.
Leading the Global Charge
Pfizer partners with the mBC community to support initiatives and organizations that help people with mBC. As part of the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC mBC Challenge) initiative, launched in 2015, Pfizer has partnered with the Union for International Cancer Control (UICC) to award more than $1.3 million in funding to organizations to support projects that address the specific needs of mBC patients globally. Â Â
Pfizer will support the SPARC Metastatic Breast Cancer Challenge Master Course Workshop and will participate in multiple SPARC presentations and program activities.
Pfizer will also be discussing early breast cancer detection and genetic testing policies in the following presentations:
- âBarriers and opportunities in genetic testing for BRCA gene mutations in Europe: a strategic policy response to support women and families at risk of breast cancerâ â focuses on the importance of ensuring pathways and policies are in place to integrate the patient experience into comprehensive care pathways and national cancer control plans.
- âSupporting breast cancer early detection and diagnosis: A global metastatic breast cancer policy analysis and promising practice from Brazilâ â centers on breast cancer/mBC policy development in 16 countries and identifying opportunities for improvement.
Long after the Congress concludes, Pfizer continues to work with the broader cancer community to support people with breast cancer, so they can live their best lives despite their disease.
MSD is proud to support the 2018 World Cancer Congress (WCC) in Kuala Lumpur. During this yearâs congress, we will be hosting a series of sessions including a moderated expert panel on the role of public-private partnerships to increase access to innovation and immunotherapy, and a full programme for top executives of UICC member organizations with networking and workshopping opportunities as part of the CEO programme.
Satellite Symposia: Innovative Access Solutions for Immunotherapy Through Public-Private Partnerships
October 2, 2018 - 2:20 PM
Unprecedented medical advancements have contributed to great progress in cancer care. Innovative treatment strategies, such as immunotherapy, hold promise to improve outcomes for patients across multiple types of cancer. However, barriers to accessing this innovation remain. This interactive session will bring together patients, health care providers, industry and policy makers to consider the role of public-private partnerships in addressing these challenges.
Building on its tremendous success at the 2016 World Cancer Congress, MSD is proud to sponsor UICC's flagship programme tailored for CEOs of UICC membership. At this yearâs Congress, executives will work with a culturally diverse group of peers, and leave the event armed with practical solutions to help them address unique business challenges. This yearâs programme includes three interactive lunch workshops, a private networking reception and a CEO Award, which will be presented at the General Assembly.Â More information is available onÂ the CEO programme page.
The Tata Trusts isÂ proud to support Capacity Building activities at the 2018 WCC, as well as UICC membership for new organisations from India.
New cancer care model in India
The Tata Trusts in partnership with the Government of India, are rolling out a national step-down distributed cancer centre model, commencing initially in north-east India. In contrast to the current situation where one hospital handles a cancer patientâs journey end-to-end, the model proposes smaller centres close to patientsâ home and interlinked with the apex centres, handle diagnosis and care delivery, thereby providing high quality cancer care closer to home. The vision is to create patient-centric cancer centres to deliver standardised and affordable care close to patientsâ homes. The programme has six key factors (Infrastructure development /Â Awareness, prevention, and early detection /Â Community and hospital palliative care /Â Integration of clinical guidelines and training /Â Human resource development /Â Technology to link centres)
The network will have three levels:
Level 1: comprehensive cancer centres (around 200 beds) providing services ranging from diagnostics to complex therapies and research
Level 2: cancer centres (around 100 beds) located near existing government medical colleges offering common diagnostic and treatment services with complex care being delivered at level 1
Level 3: stand-alone day care cancer units near district hospitals offering diagnostics, chemotherapy, and radiotherapy
Awareness, prevention, and early detection
Health communication, prevention, and screening programmes for early detection thereby shifting the patient profile from late to early stage and improving survival rates.
Community and hospital palliative care given that today more than 60 percent cancers are presented at a late stage
Integration of clinical guidelines and training
Through the National Cancer Grid, a coalition of more than 130 cancer centres in India.
Human resource development
Up-skilling and para-skilling the health-care workforce. Developed by the National Cancer Grid as short term fellowships and certificate courses which will be accredited through state health universities.
Technology to link centres
Implementation of a Digital Nerve Centre to ensure seamless flow of patient information across centres. All the centres will be linked through tele-radiology, tele-pathology, and virtual tumour boards
Advancing towards personalised healthcare
Scientists have begun to understand, target, and diagnose illnesses on a molecular level. Cancer, for instance, is not one disease. We are now aware that there are 250 to 300 types and subtypes of cancer. Doctors can identify the drivers of the disease and therefore better predict how well a patient is going to respond to a treatment.
With the help of diagnostic tools, specific genetic defects or other malfunctions can be detected and treated.
In an era of digital technology, we will be able to increasingly tailor medical treatment to the needs of individuals and small groups of patients. Far more information will be captured, stored and analysed to learn how diseases manifest themselves and how patients experience them day-to-day. Combined with a deeper understanding of molecular science and new methods for diagnostics, this will bring disruptive change to how we research, develop, approve and pay for medicines, as well as how patients and their physicians make decisions about whether, when and how to treat.
Who does PHC Benefit?
- Increased confidence in treatment decisions and improved outcomes for patients
- Improved quality of life and lifetime gained
- Fewer unnecessary treatments and associated costs through smarter decisions on whether, when and how to treat
- More efficient use of funds in the healthcare system
- Higher cure rates
How Do we Get There?
Enabling healthcare systems around the world to build their capacity for PHC will require multi-sectoral collaboration and the knowledge and expertise of all stakeholders.
Join us for the Roche-sponsored session: âWhat is the real value of Personalised Healthcare?â to explore the value that stakeholders assign to personalised healthcare and discuss how we can collaborate to move PHC forward.
Wednesday, 3rd October 2018 / 09:00 - 10:30 / Room 302-303
Canadian Partnership Against Cancer (CPAC)
UICC Member and Partner
Sharing Canadaâs 10-years of progress with the global cancer community
Evidence shows that countries with a national cancer strategy are more successful in making progress in cancer control. More than a decade ago, the Canadian cancer community came together to create one of the first such strategies. The Canadian Strategy for Cancer Control set out three ambitious 30-years goals: that fewer Canadians develop cancer, fewer die from cancer, and those affected by cancer have a better quality of life.
The Canadian Partnership Against Cancer was created in 2006 to move the Strategy into action, working with partners throughout the system to implement it and measuring its progress. To do this, we created a network model that established collaborative relationships with the provinces and territories, non-governmental organizations, researchers, health professionals and many others.
At the 2018 World Cancer Congress, we will present abstracts and participate in panels to share lessons learned, highlight accomplishments, and point to the work still to be done to achieve our 30-year goals. This includes leading two sessions with international colleagues, one focusing on how to overcome barriers to implement colorectal cancer screening in different jurisdictional settings, and one looking at why adolescents and young adults with cancer need our attention. We also hope to solicit international advice on how we can refresh our national strategy.
We look forward to learning about the advances in cancer control that will be presented at the World Cancer Congress, contributing to the momentum of shared successes and discussing innovative ways to meet the challenges ahead.
Please view the sessions that involve the Canadian Partnership Against Cancer within the main programme.
2018 Congress Gold Sponsor
The C3 Prize ChallengeÂ
Do you have a passion for healthcare innovation and have an idea that may improve cancer care in low-and middle-income countries?Â
If so, we want to hear from you! The Astellas Oncology C3 PrizeÂ® is a global challenge aimed at inspiring novel non-treatment ideas that may improve cancer care for patients and their loved ones. Launched in 2016, this yearâs challenge will focus on solutions for cancer care in low-and middle-income countries, which bear a disproportionate burden of the global cancer epidemic.
The Astellas Oncology C3 Prize will award three prizes totaling $100,000 USD (one $50,000 USD and two $25,000 USD grants). In addition to the prize money, winners will receive a one-year ânights and weekendsâ membership to MATTER to help bring their ideas to life.
Applications are being accepted now through July 25, 2018 at www.C3Prize.com.
UICC and the 2018 World Cancer Congress are delighted to partner with Astellas in inviting innovators like you who want to improve cancer care to propose ideas that address specific challenges encountered in low-and middle income countries within the following three categories: support tools, educational tools and technology.
Three category winners will be flown to Kuala Lumpur to present their ideas to a live panel of judges at the World Cancer Congress on October 3, 2018.Â
According to the 2017 Astellas Oncology C3 Grand Prize winner, HernÃ¢ni Oliveira, University of Porto, Portugal: "With the Astellas Oncology C3Â Prize, we have been able to quickly move our idea from concept to reality, and fulfill our goal of helping families facing cancer better adapt to their new reality. I encourage anyone with an innovative idea that could help change cancer care to apply to this challenge. The entire experience is beyond rewarding.â
More information about the awards and submission criteria can be found at:Â www.C3Prize.com. Please share this information with your colleagues, friends and family â anyone who may have the next winning idea!
See terms and conditions at www.c3prize.com for full challenge rules and eligibility. Void where prohibited. No purchase necessary. No entries after July 25, 2018 at 11:59pm CST. http://www.c3prize.com/SubmissionGuidelines.aspx#terms-and-conditions